Holen Sie sich die Stockscreener-App
10.14
0.05%
0.005
Handel nachbörslich:
10.15
0.005
+0.05%
Churchill Capital Corp Xi Aktie (CCXI) Neueste Nachrichten
Art Technology Acquisition Corp.: Performance & Quotes, ARTC Stock Price on Nasdaq Exchange - marketscreener.com
SPACSphere Acquisition Corp.: Performance & Quotes, SSAC Stock Price on Nasdaq Exchange - marketscreener.com
Soren Acquisition Corp.: Performance & Quotes, SORN Stock Price on Nasdaq Exchange - marketscreener.com
CCXI Technical Analysis & Stock Price Forecast - Intellectia AI
MML Acquisition Stock (MML.H)Quote Toronto S.E. - marketscreener.com
MML Acquisition: Dividend historical data and projections - marketscreener.com
White Pearl Acquisition Corp.: Performance & Quotes, WPAC Stock Price on Nyse Exchange - marketscreener.com
Eagle Nuclear Energy Corp.: Dividend historical data and projections - marketscreener.com
Eagle Nuclear Energy Corp.: Shareholders Board Members Managers and Company Profile | US2697101093 - marketscreener.com
Eagle Nuclear Energy Corp.: Performance & Quotes, NUCL Stock Price on Nasdaq Exchange - marketscreener.com
Mountain Lake Acquisition Corp.: Dividend historical data and projections - marketscreener.com
Lake Superior Acquisition Corp.: Dividend historical data and projections - marketscreener.com
Free float of Churchill Capital Corp XI – BOATS:CCXIW - TradingView
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
MML Acquisition Corp.: Dividend historical data and projections - marketscreener.com
Churchill Capital Corp XIUnits (NQ: CCXIU - The Chronicle-Journal
Trailblazer Holdings, Inc.: Dividend historical data and projections - marketscreener.com
Magnetar Financial LLC Acquires 2,700,000 Shares in Churchill Ca - GuruFocus
DermTech Stock (DMTK)Quote OTC Markets - marketscreener.com
CCXIW Stock Price, News & Analysis - Stock Titan
Churchill Capital Corp XI(NasdaqGM: CCXI) added to NASDAQ Composite Index - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026 - The Manila Times
Churchill Capital Corp XI Announces Separate Trading of Shares and Warrants - TradingView
IPO buyers in Churchill Capital XI can trade stock and warrants separately - Stock Titan
US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request - Citeline News & Insights
Asking Amgen to withdraw Tavneos, FDA revisits years-old data issue - BioCentury
Amgen thumbs-down on FDA’s ask, Tavneos sales continue - BioWorld MedTech
Amgen resists FDA request to pull rare disease drug Tavneos from the market - Fierce Pharma
Amgen’s Revenue Gains Outweigh News That FDA Wants Tavneos Pulled From Market - Citeline News & Insights
Amgen Defends Tavneos Benefit-Risk Profile Following FDA Withdrawal Request - Medical Professionals Reference
US FDA Wants Tavneos Pulled From Market, Amgen Declines - Citeline News & Insights
EMA reviewing Amgen’s vasculitis drug over trial ‘data integrity’ - BioWorld MedTech
Horizon (HRZN) and Monroe Capital (MRCC) outline proxy drive for proposed merger and asset sale - Stock Titan
1 km lidar partnership for safer cars, trains and transport systems - Stock Titan
Rough Price Target for a Promising Quantum Computing Name Working With Nvidia - TheStreet Pro
CCCXChurchill Cap Corp X Latest Stock News & Market Updates - Stock Titan
Churchill Capital Corp X (CCCX) Stock News on Dec. 24, 2025: Infleqtion Quantum SPAC Deal, Latest Catalysts, and What Comes Next - TechStock²
Churchill Capital Corp XI completes $414 million IPO and private placement - Investing.com
Infleqtion Chief Scientist for Quantum Information Dr. Mark Saffman Awarded the John Stewart Bell Prize - 01net
U.S. IPO Weekly Recap: Medline Headlined Final Week Before Christmas - Seeking Alpha
Churchill Capital Corp XI completes $414 million IPO on NASDAQ - Investing.com Nigeria
Churchill Capital Corp XI Announces the Pricing of Upsized $360 Million Initial Public Offering - Yahoo Finance
Another SPAC Boom is Coming; And It’s Stronger than Ever - themiddlemarket.com
Deal Watch: Skadden, Davis Polk, Wachtell, Cravath Lead $20B Deals, as Mega M&A Continues - Law.com
IPO NewsUS IPO Weekly Recap: 2 IPOs come to market, pipeline grows ahead of Thanksgiving holiday week - renaissancecapital.com
3 Firms Lead Churchill Capital's Latest $300M SPAC Filing - Law360
Canaan (NASDAQ: CAN) closes $72M registered direct offering; ADSs at $1.131 - Stock Titan
Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. - Newsfile
Anca Vasculitis Drug Market Set for Dynamic Rise with Key Players ChemoCentryx, Inc. and Vifor Pharma - openPR.com
Trump, Xi to Talk in Person; CPI on Tap; Oh, Boy, Canada! - TheStreet Pro
Infleqtion: Quantum Computing And More—Real Revenue At A Huge Discount - Seeking Alpha
Steam demo Oct 15 — GCL's Island of Hearts live-action game launches Spring 2026 with creator cast - Stock Titan
Churchill Capital Corp X Shares Jump After Citron Research Calls It a Top Quantum Trade - MSN
First-Ever Bank Rewards to Crypto: JPMorgan to Allow Chase Points Transfer to Coinbase Wallets - Stock Titan
ChemoCentryx Target of Unusually High Options Trading (NASDAQ:CCXI) - 富途牛牛
Oklo Tumbles After Klein Sells Nuclear Developer Shares - Bloomberg.com
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board - The Globe and Mail
Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix - TheStreet
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Latham-Backed Drug Developer's Statements Can't Be Proven False, N.D. Cal. Judge Finds - Law.com
Amgen's ChemoCentryx prevails in investor lawsuit centered on autoimmune drug Tavneos - Fierce Pharma
Pharma Company Beats Investor Suit Over Drug Safety Claims - Law360
Doctored data, protest from trial observers: Lawsuit points to alleged misconduct at Amgen-bought biotech - Fierce Pharma
NVIDIA Certifies AEye's Apollo Lidar for Autonomous Driving Platform, Opening Door to Major Automakers - Stock Titan
Massive Edge AI Deal: Blaize Secures $56M Contract to Power 250K Smart Surveillance Systems in Southeast Asia - Stock Titan
DC-Area REIT Saul Centers Keeps Steady Dividend Stream with Latest $0.59 Payout - Stock Titan
Foley Automotive Update- June 11, 2025 - The National Law Review
CCCXUChurchill Capital Corp X Latest Stock News & Market Updates - Stock Titan
Michael Klein's Latest SPAC Raises Massive $414M IPO as Churchill Capital Sees Strong Demand - Stock Titan
Mullen's Dramatic 1:100 Stock Split Aims to Save Nasdaq StatusKey Details Revealed - Stock Titan
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Financial Crisis: Mynaric Set for Nasdaq Exit as Restructuring and Compliance Issues Mount - Stock Titan
0.45%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):